Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20239132 | 0.91 | DGAT2 (0.46) | DGAT2PDE10AJAK1SMN1; SMN2IGF1R | |
| SCHEMBL16738674 | 0.86 | DGAT2 (0.57) | DGAT2KDM4EPDE4BVNN1MET | |
| SCHEMBL20239333 | 0.85 | DGAT2 (0.56) | DGAT2KDM4EPDE4BVNN1MET | |
| SCHEMBL20239203 | 0.85 | DGAT2 (0.59) | DGAT2KDM4EPDE4BVNN1MET | |
| SCHEMBL20239171 | 0.84 | DGAT2 (0.56) | DGAT2KDM4EPDE4BVNN1MET | |
| SCHEMBL20239227 | 0.84 | DGAT2 (0.56) | DGAT2KDM4EVNN1CYP3A4SMN1; SMN2 | |
| SCHEMBL20239176 | 0.84 | DGAT2 (0.55) | DGAT2KDM4EVNN1CYP3A4SMN1; SMN2 | |
| SCHEMBL20239169 | 0.83 | DGAT2 (0.54) | DGAT2KDM4EVNN1CYP3A4SMN1; SMN2 | |
| SCHEMBL18249757 | 0.83 | DGAT2 (0.54) | DGAT2KDM4EVNN1SMN1; SMN2 | |
| SCHEMBL20239295 | 0.83 | SMN1; SMN2 (0.43) | DGAT2PDE4BPDE4DJAK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298001-B1 | DGAT2 INHIBITORS | LILLY CO ELI (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10053429-B2 | DGAT2 inhibitors | ELI LILLY AND COMPANY (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | DGAT2 1/4885PDE10A 2191/4885KDM4E 4070/4885 |
| US-10053429-B2 | DGAT2 inhibitors | DGAT2, DGAT1, LCAT | DGAT2 1/4885PDE10A 2330/4885KDM4E 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.